Expertise in
14
conditions

Dr. Brian D. Weiss

Hematology | Oncology
Riley Hospital For Children At Indiana University Health
705 Riley Hospital Dr, 
Indianapolis, IN 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
14
conditions
Riley Hospital For Children At Indiana University Health
705 Riley Hospital Dr, 
Indianapolis, IN 

Overview

Brian Weiss is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana.

Dr. Weiss is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Neurofibromatosis, Lithotripsy, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 72 peer reviewed articles and participating in 21 clinical trials. Dr. Weiss is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Riley Hospital for Children at Indiana University Health
705 Riley Hospital Dr, Indianapolis, IN 46202

Additional Areas of Focus

Dr. Weiss has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors
Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors
Enrollment Status: Recruiting
Publish Date: August 24, 2026
Intervention Type: Combination product
Study Drug: Selumetinib
Study Phase: Phase 2
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Dinutuximab, Isotretinoin, Lenalidomide
Study Phase: Phase 1
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib
Study Phase: Phase 4
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Study Phase: Phase 1
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Enrollment Status: Active_not_recruiting
Publish Date: June 23, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

72 Total Publications

Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma.
Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma.
Journal: Science advances
Published: July 17, 2026
Similar Doctors
Expertise in
6
conditions
Dr. Amy D. Shapiro
Hematology | Oncology
Expertise in
6
conditions
Dr. Amy D. Shapiro
Hematology | Oncology
Referral may be required

Indiana Hemophilia And Thrombosis Center Inc

8326 Naab Rd, 
Indianapolis, IN 
 (9.0 miles away)
317-871-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Amy Shapiro is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Shapiro is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Blood Clots, Hemophilia A, Hemophilia B, and Ligneous Conjunctivitis. Dr. Shapiro is currently accepting new patients.

Expertise in
29
conditions
Dr. Daniel A. Rushing
Hematology | Oncology
Expertise in
29
conditions
Dr. Daniel A. Rushing
Hematology | Oncology
Referral may be required

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (0.2 miles away)
317-948-8310
Languages Spoken:
English
See accepted insurances

Daniel Rushing is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Rushing is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Fibrosarcoma, and Bone Tumor.

Expertise in
7
conditions
Dr. Steven D. Rhodes
Hematology | Oncology
Expertise in
7
conditions
Dr. Steven D. Rhodes
Hematology | Oncology
Referral may be required

Riley Hospital For Children At Indiana University Health

705 Riley Hospital Dr, 
Indianapolis, IN 
 (0.1 miles away)
317-944-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Rhodes is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Rhodes is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis Type 1 (NF1), Neurofibromatosis, RASopathies, and Malignant Peripheral Nerve Sheath Tumor. Dr. Rhodes is currently accepting new patients.

Frequently Asked Questions about Dr. Brian D. Weiss

How do I make an appointment with Dr. Brian D. Weiss?

You can book an appointment with Dr. Brian D. Weiss by calling their office at 317-944-2143. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brian D. Weiss a top-rated expert for Neuroblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brian D. Weiss is classified as an Elite expert for Neuroblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brian D. Weiss specialize in?

While Dr. Brian D. Weiss is a Hematology, they have specific expertise in Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Neurofibromatosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Brian D. Weiss participate in research or clinical trials?

Yes. Dr. Brian D. Weiss has published 72 articles and abstracts on conditions like Neuroblastoma. You can view a list of Dr. Brian D. Weiss's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brian D. Weiss accept my insurance?

Dr. Brian D. Weiss accepts most major insurance plans, including Anthem BCBS and CareSource. We recommend calling the office directly at 317-944-2143 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weiss's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile